Our dedicated Software and Technology professionals have extensive experience working with investors to make the right investment decisions. Our professionals collectively look at more than 100 software and technology companies each year, provide the “best in class” quality of earnings analyses and are subject matter experts in revenue recognition and revenue based analyses.
Clients often turn to us early in the process to assist in building market standard renewal rate analyses, customer cohort analyses and gross margin profiles, which U.S. GAAP reporting standards do not address and can leave significant room for interpretation by sellers. We help investors and those new to the space adopt standardized, comparable metrics, beyond EBITDA, to evaluate potential investments and the performance of their portfolio companies.
Our professionals work with investors to help them understand the impact of upcoming changes to domestic and international accounting standards on software companies and SaaS providers, to help them avoid misinterpreting revenue trends when looking at potential investments or working with their portfolio companies. With the right industry expertise, A&M can help you maximize the value for every transaction and avoid post-transaction surprises.
Infrastructure Pulse Survey Report: Spring 2026, North America and Europe
May 14, 2026
The Infrastructure Pulse Survey Report for Spring 2026, published by Alvarez & Marsal in collaboration with the Global Infrastructure Investor Association (GIIA), offers an insight into how investors across North America and Europe are reading the current investment landscape through a period of macroeconomic and geopolitical uncertainty.
Alvarez & Marsal Continues to Strengthen Transaction Advisory Practice in Australia with Senior Talent
May 13, 2026
Alvarez & Marsal (A&M), a leading global professional services firm, today announced the appointment of Sydney-based Roshan Emmanuel as a Managing Director within its Global Transaction Advisory Group (Global TAG), underscoring the firm’s rapid growth and continued investment in the Australian market.
Carving Out Success: Life Sciences Companies Are Rationalizing Portfolios by Divesting Non-Core Assets
May 12, 2026
Historically, large healthcare and life sciences corporations have focused deal activity on a breadth of diverse assets. However, the landscape is undergoing significant transformation as businesses shift to rationalize their portfolios and invest in fewer core areas.
Alvarez & Marsal’s Global Transaction Advisory Group Continues to Expand Senior Talent Ranks in Europe
May 6, 2026
The practice welcomes new Managing Directors Tobias Ranker and Eric Poitevin to support growth in Germany and France